Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

C International Conference on Molecular Targets and Cancer Therapeutics in a poster titled "A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer," Abstract No. A158.

On Wednesday, October 24, 2007 at the AACR-NCI-EORTC meeting, Sunesis will present additional non-clinical data in a poster titled "SNS-595 potentiates the in vivo activity of carboplatin, cisplatin and gemcitabine in solid tumor xenografts," Abstract No. B285. This poster presentation will take place in Poster Session B -- Other Small Molecule Therapeutics.

About SNS-595

SNS-595 is a replication-dependent DNA damaging agent that causes irreversible G2 arrest and rapid apoptosis. A secondary mechanism for SNS-595 is a unique inhibition of topoisomerase II that causes highly selective DNA damage.

Data reported today build upon positive results from non-clinical studies, and from Sunesis' dose-escalating Phase 1 clinical trial of SNS-595 in which an ovarian cancer patient with advanced disease achieved a PR. In addition to the Phase 2 clinical trial in ovarian cancer patients, SNS-595 is currently being evaluated in two Phase 1b acute leukemia clinical trials. In clinical trials conducted to date, SNS-595 has been generally well tolerated and has shown objective responses in both solid and hematological tumor types. In non-clinical evaluations, SNS-595 demonstrates broad and potent activity in xenograft, syngeneic and drug-resistant models.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2007 there will be an estimated 22,430 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. The front-line treatment for ovarian cancer is typically a combination of a taxane and a platinum dru
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
(Date:4/23/2014)... in the popular Swedish children,s TV show Bolibompa, ... A new study from the University of Gothenburg ... programmes as well as the link between young ... , Steingerdur Olafsdottir,s doctoral thesis focuses on the ... TV show Bolibompa. Healthy foods dominated in the ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... BlueCross BlueShield of South Carolina announced today that the ... held during lunchtime hours on Wednesday, April 29, 2009.Blue ... well as other employers, will encourage their employees to ... in a 30-minute lunchtime walk. The goal of National ...
... 2 Accelerated Community Oncology Research Network (ACORN(TM)), ... highlights of its annual Principal Investigators, Meeting held ... from community-based oncology practices throughout the United States ... emerging treatment trends, as well as promising new ...
... to Include 24-oz and Convenient 4-oz Travel Size ... (Nasdaq: PURE ) today announced an ... PURE,s silver dihydrogen citrate (SDC)-based disinfectant as OneShot ... OneShot Plus product line. OneShot Plus DD ...
... BIGLERVILLE, Pa., March 2 The first Eklin ... recently installed at Dr.,Flake,s Animal Wellness Clinic which ... Oxford. The state-of-the-art system,from Eklin Medical Systems, the ... benefit the area,s thousands of veterinary patients,supporting the ...
... SynCare, LLC, announces the extension of its contract ... management. MHS, a Medicaid Managed Care Company, serving SCHIP ... assist the company in providing comprehensive care and support ... to continuing our partnership with SynCare for prenatal care ...
... are vegans and vegetarians most affected, study says , , MONDAY, March ... B12 in their blood before and after conception have a greater ... a new study says. , Most at risk may ... meat and animal-based foods, noted an American and Irish research team ...
Cached Medicine News:Health News:S.C. BlueCross to Celebrate Third Annual National Walk @ Lunch Day With Community Events in Columbia, Charleston, Greenville 2Health News:ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting 2Health News:ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Dr. Flake's Animal Wellness Clinic Installs Adams County's First Eklin Digital Radiography System 2Health News:Dr. Flake's Animal Wellness Clinic Installs Adams County's First Eklin Digital Radiography System 3Health News:SynCare Receives Managed Health Services Contract Renewal 2Health News:B12 Deficit May Boost Risk of Birth Defects 2
... Control is a liquid control ... busy immunoassay laboratory. With a ... serum based control can replace ... products for immunoassay and therapeutic ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
The Acceava Trichomonas Rapid Test is an immunochromatographic assay that detects pathogen antigens directly from vaginal swabs. Results are rapid, occurring within approximately 10 minutes....
Medicine Products: